Tylosin A Derivatives for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limited use of tylosin A in human and veterinary medicine due to its short half-life and poor oral bioavailability, as well as susceptibility to hepatic esterases, particularly for derivatives esterified at the 4″-position on the mycarose sugar, hinders its effectiveness as an orally bioavailable antibiotic.
Innovation Solution
Development of tylosin A derivatives with esterase-resistant substituents at the 4″-hydroxyl group and optional acylation at the 2′-hydroxyl, leading to compounds with improved pharmacokinetic properties and retention of antibiotic activity, suitable for oral dosing and effective against Gram-positive and some Gram-negative bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tylosin A is used as an orally administered antibiotic, then it provides broad-spectrum activity against Gram-positive organisms, but it exhibits poor oral bioavailability and short half-life
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of tylosin A through derivatization at specific positions (4''-position of mycarose sugar and 2'-position of desosamine sugar). These structural modifications alter the pharmacokinetic parameters of the molecule, resulting in extended half-life and improved oral bioavailability while preserving antibiotic activity. Specific derivatives include esters with half-lives extended from hours to days.
Solution Approach 2:
The patent creates composite molecular structures by combining tylosin A core with additional functional groups and substituents. The derivatives incorporate multiple chemical moieties including esters, amides, and various sugar modifications, forming composite antibiotic molecules that achieve both prolonged duration of action and maintained efficacy.
2Reliability
If tylosin A derivatives are esterified at the 4''-position on the mycarose sugar to improve pharmacokinetic properties, then absorption is enhanced, but susceptibility to hepatic esterases increases
Solution Approach 1:
The patent applies local quality by making site-specific modifications at the 4''-position of the mycarose sugar rather than global structural changes. By targeting this specific location with carefully selected ester groups, the patent enhances oral bioavailability locally at the absorption site while the overall molecular structure remains resistant to hepatic esterase degradation.
Solution Approach 2:
The patent converts the potential harm of esterase susceptibility into benefit by using esterification strategically. The ester groups are positioned and designed to protect against hepatic esterase attack while enabling improved absorption. The ester modifications that initially might seem to increase esterase susceptibility actually serve as protective groups that enhance overall pharmacokinetic profile.
3Adaptability or versatility
If tylosin A derivatives are developed with improved pharmacokinetic properties for human use, then treatment options expand, but development is hindered by marginal pharmacokinetic profiles and esterase susceptibility
Solution Approach 1:
The patent applies segmentation by dividing the tylosin A molecule into distinct functional regions that can be independently modified. The 4''-position of mycarose sugar and 2'-position of desosamine sugar are treated as separate modification sites, allowing systematic exploration of derivatives with different pharmacokinetic properties while maintaining the core antibiotic structure.
Data Source
AI summary
The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.